<DOC>
	<DOCNO>NCT02124902</DOCNO>
	<brief_summary>This single arm open label phase II study woman clinical stage 2 3 triple negative breast cancer assess anti-tumor activity ( term pathologic complete response rate ) neoadjuvant docetaxel combination carboplatin . Patient derive xenograft also develop simultaneously purpose genoproteomic analysis .</brief_summary>
	<brief_title>Neoadjuvant Treatment Triple Negative Breast Cancer Patients With Docetaxel Carboplatin Assess Anti-tumor Activity</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Newly diagnose clinical stage II III breast cancer complete surgical excision breast cancer neoadjuvant chemotherapy treatment goal . Patients PR+ tumor allow . HER2 negative FISH IHC stain 0 1+ . ER le Allred score 3 less 1 % positive staining cell invasive component tumor Tumor size least 2cm one dimension clinical radiographic exam ( WHO criteria ) . Patients palpable lymph node may enrol regardless tumor size . At least 18 year age . ECOG performance status ≤ 2 Normal bone marrow organ function define : Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcl Platelets ≥ 100,000/mcl Serum bilirubin within ( ) normal limit ( OR total bilirubin ≤ 3.0 x IULN direct bilirubin within normal range patient well document Gilbert Syndrome ) AST ( SGOT ) /ALT ( SGPT ) within ( ) normal limit Creatinine clearance ≥ 60 mL/min/1.73 m2 Patients may pre postmenopausal . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative , applicable ) . If consent participate optional PET/MR imaging substudy , patient must able tolerate PET/MRI intravenous contrast administration must complete applicable MRI screen evaluation form Prior systemic therapy indexed breast cancer . A history malignancy ≤ 5 year previous exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix . Patients bilateral inflammatory breast cancer . Currently receive investigational agent . A history allergic reaction attribute compound similar chemical biologic composition docetaxel carboplatin . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant and/or breastfeeding . Patient must negative serum pregnancy test within 7 day study entry premenopausal . Known HIVpositivity . Sentinel lymph node biopsy For patient agree participate PET/MR imaging : renal insufficiency ( glomerular filtration rate ( GFR ) &lt; 30 mL/min/1.73 m2 ) measure within past 60 day precludes safe administration contrast agent dialysis prior allergic reaction gadoliniumbased MR contrast agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>